12/06/2018
Fidia Pharma Group has completed the acquisition of Sooft
The acquisition gives an added boost to Fidia’s leadership in the national and international ophthalmology market segment
Abano Terme (PD), June 11, 2018 – Fidia Pharma Group, an Italian multinational company, leader in the R&D, manufacturing and sales of a wide range of products mainly based on hyaluronic acid, announced today the closing of the acquisition of Sooft, #1 Italian ophthalmic company in Italy , by acquiring Efil shareholders' remaining minority shares, thereby achieving 100% controlling ownership. With the closing of the transaction, which began in March 2017 and was finalized on terms agreed upon with the selling party, Fidia is pleased to report a solid business performance, underlying how, after one year since Sooft takeover, results are in line with expectations.
«After one year of hard teamwork and determination – explains Carlo Pizzocaro, President of Fidia Pharma Group – aiming at reinforcing Fidia Pharma Group’s ranking in the ophthalmology market segment, we are pleased to report that Sooft has fortified its position – revenues exceeded 70 million Euros - in a competitive and constantly evolving marketplace environment with interesting growth potential, and Fidia as a major key player in the Italian market».
The completion of the operation will enable Fidia, who was active in the eye care segment in previous years, to consolidate its know-how and strengthen its role in this area, by including hi-tech, innovative products in its portfolio, a growth driver for the Group as a whole, both in national and international markets.
Sooft is active in the treatment of all major conditions that affect the eye, and operates through Sooft, Bioos, Glaucoom, OftaH.T. e Neoox trademarks. The company owns 27 patents, further bolstering Fidia Pharma Group’s already strong portfolio, consisting of more than 900 patents, of which over 650 on hyaluronic acid with different molecular weights.
«After one year of hard teamwork and determination – explains Carlo Pizzocaro, President of Fidia Pharma Group – aiming at reinforcing Fidia Pharma Group’s ranking in the ophthalmology market segment, we are pleased to report that Sooft has fortified its position – revenues exceeded 70 million Euros - in a competitive and constantly evolving marketplace environment with interesting growth potential, and Fidia as a major key player in the Italian market».
The completion of the operation will enable Fidia, who was active in the eye care segment in previous years, to consolidate its know-how and strengthen its role in this area, by including hi-tech, innovative products in its portfolio, a growth driver for the Group as a whole, both in national and international markets.
Sooft is active in the treatment of all major conditions that affect the eye, and operates through Sooft, Bioos, Glaucoom, OftaH.T. e Neoox trademarks. The company owns 27 patents, further bolstering Fidia Pharma Group’s already strong portfolio, consisting of more than 900 patents, of which over 650 on hyaluronic acid with different molecular weights.
